SCHEMBL2758261

SCHEMBL2758261

CC(C)(C)OC(=O)N1CCC2(CC1)C[C@H](NC(=O)C1CC1)c1ccccc12

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 3/20 0.46
NAE1 Q13564 1/20 0.45
UBA3 Q8TBC4 1/20 0.45
IDO1 P14902 1/20 0.45
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN6 P29350 1/20 0.44
STS P08842 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
GPR119 Q8TDV5 2/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
KMT2A Q03164 1/20 0.41
NAMPT P43490 1/20 0.41
MCHR2 Q969V1 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2758276 0.96 KDM1A (0.47) KDM1ANAE1UBA3IDO1PTPN2
SCHEMBL12385458 0.89 MCHR2 (0.50) KDM1ANAE1UBA3IDO1HDAC1
SCHEMBL2758260 0.89 NAE1 (0.46) KDM1ANAE1UBA3IDO1HDAC1
SCHEMBL8314152 0.88 NAE1 (0.47) KDM1ANAE1UBA3IDO1HDAC1
SCHEMBL2758247 0.87 KDM4E (0.50) KDM1ANAE1UBA3IDO1HDAC1
SCHEMBL2758278 0.87 NAE1 (0.44) KDM1ANAE1UBA3IDO1HDAC1
SCHEMBL2758262 0.87 HSD11B1 (0.46) KDM1ANAE1UBA3IDO1HDAC1
SCHEMBL8312069 0.85 NAE1 (0.48) KDM1ANAE1UBA3IDO1STS
SCHEMBL12084830 0.85 KDM1A (0.46) KDM1ANAE1UBA3IDO1HDAC1
SCHEMBL242181 0.84 KDM1A (0.46) KDM1ANAE1UBA3IDO1PTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304423-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICAL INCORPORATED (US) 2012-11-06 US disclosed
US-8304423-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICAL INCORPORATED (US) 2012-11-06 US disclosed
US-20120196857-A9 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-02 US disclosed
US-20120196857-A9 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-02 US disclosed
US-20120004226-A1 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-05 US disclosed
US-20120004226-A1 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-05 US disclosed
US-8003660-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-08-23 US disclosed
US-8003660-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-08-23 US disclosed
US-20070213315-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2007-09-13 US disclosed
US-20070213315-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2007-09-13 US disclosed
WO-2007100664-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213315-A1 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 KDM1A 2615/4885NAE1 3445/4885UBA3 3599/4885
US-20120004226-A1 Modulators of Muscarinic Receptors CHRM3, CHRM5, CHRM2 KDM1A 2615/4885NAE1 3445/4885UBA3 3599/4885
US-20120196857-A9 Modulators of Muscarinic Receptors CHRM3, CHRM5, CHRM2 KDM1A 2615/4885NAE1 3445/4885UBA3 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.